FDA WARNING_LETTER - SnugZ USA, Inc. - May 01, 2026

SnugZ USA, Inc. received a warning letter from the FDA following an inspection of its West Jordan, Utah facility from April 27 to May 1, 2026. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations, resulting in the firm’s over-the-counter drug products being classified as adulterated under the Federal Food, Drug, and Cosmetic Act. A primary concern was the company"s routine failure to investigate out-of-specification test results; instead, the firm frequently retested failing samples until obtaining a passing result without scientific justification. Additionally, the firm failed to adequately investigate customer complaints or verify the identity of incoming raw materials, often relying solely on supplier documentation. The FDA noted that the company’s Quality Unit lacked the necessary authority and oversight to ensure compliance, highlighting these as repeat violations from a 2022 meeting. To remediate these issues, the FDA requires SnugZ USA to hire an independent consultant to conduct a comprehensive audit of their manufacturing systems. The company must also perform a retrospective review of all failing test results and customer complaints from the past three years, conduct laboratory testing on retained product samples currently on the market, and establish scientifically sound laboratory and supplier qualification procedures. Failure to address these violations promptly may lead to legal action, including product seizures or injunctions.